Therapy Areas: AIDS & HIV
Mount Sinai, AllerGenis Partner to Bring Novel, Precision Diagnostics to Food Allergy Patients
8 November 2018 - - US-based diagnostic company AllerGenis, LLC has inked a partnership agreement with Mount Sinai Health System to develop and commercialise technology for improved food allergy detection and patient management, the company said.

The diagnostic technology will provide information to both patients and clinicians.

Through this partnership, Mount Sinai has licensed its proprietary epitope mapping platform to AllerGenis. Epitope mapping is the process of identifying the binding site of an antibody on its target antigen and is instrumental in the development of this new level of diagnostics.

AllerGenis will use the platform to bring novel precision diagnostics to clinicians treating patients with food allergies.

Its first product will be a peanut allergy assay, which will be available in the fall of 2019, followed by a pipeline of assays for other common food allergies including milk, egg, shellfish, and tree nuts.

The epitope mapping platform is based on immunologic research conducted by Hugh Sampson, MD, director Emeritus of the Elliot and Roslyn Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai. The platform subdivides protein allergens into smaller peptides, called epitopes, and measures the reactivity of a patient's antibody levels to these epitopes.

Each patient will have a unique epitope reactivity signature. AllerGenis is curating a growing database of human epitope signatures, which will help providers better assess and manage patients with food allergies.

More than 30m people in the United States and Europe have food allergies.

Eight percent of US children are estimated to have a food allergy, and one in 13 US children are at risk for life-threatening anaphylaxis, underscoring the urgent need for new therapies and diagnostics to accurately assess and manage patients living with food allergies.

Established in 2017 and located in Hatfield, PA, AllerGenis develops precision, data-driven diagnostics to help healthcare providers more accurately and safely diagnose, assess and monitor patients with food allergies.

The company was founded out of a collaboration between Genisphere, provider of the 3DNA platform for targeted drug delivery, and Hugh Sampson MD, of the Elliot and Roslyn Jaffe Food Allergy Institute of the Icahn School of Medicine at Mount Sinai.

AllerGenis' proprietary epitope mapping technology is based on immunological research by Dr. Sampson and leverages Genisphere's expertise in improving sensitivity of diagnostic tests. AllerGenis is creating the largest food allergy knowledge base populated by individual patient epitope signatures derived from epitope mapping, clinical history, and patient-reported outcomes to gain clinical insights.

Mount Sinai Innovation Partners is responsible for driving the real-world application and commercialisation of Mount Sinai discoveries and inventions, and the development of research partnerships with industry.

Our aim is to translate discoveries and inventions into health care products and services that benefit patients and society.

MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life.

These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially-relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities.


Related Headlines